BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 19502975)

  • 1. Effect of genetic factors on opioid action.
    Kosarac B; Fox AA; Collard CD
    Curr Opin Anaesthesiol; 2009 Aug; 22(4):476-82. PubMed ID: 19502975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Genetic polymorphisms and human sensitivity to pain and opioids].
    Nishizawa D; Nagashima M; Satoh Y; Tagami M; Ikeda K
    Masui; 2009 Sep; 58(9):1093-101. PubMed ID: 19764431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pain and genetics.
    Fernandez Robles CR; Degnan M; Candiotti KA
    Curr Opin Anaesthesiol; 2012 Aug; 25(4):444-9. PubMed ID: 22732422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic factors in pain and its treatment.
    Stamer UM; Stüber F
    Curr Opin Anaesthesiol; 2007 Oct; 20(5):478-84. PubMed ID: 17873601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current evidence for a genetic modulation of the response to analgesics.
    Lötsch J; Geisslinger G
    Pain; 2006 Mar; 121(1-2):1-5. PubMed ID: 16472919
    [No Abstract]   [Full Text] [Related]  

  • 6. Genetics of pain, opioids, and opioid responsiveness.
    Tremblay J; Hamet P
    Metabolism; 2010 Oct; 59 Suppl 1():S5-8. PubMed ID: 20837195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics in palliative care.
    Kleine-Brueggeney M; Musshoff F; Stuber F; Stamer UM
    Forensic Sci Int; 2010 Dec; 203(1-3):63-70. PubMed ID: 20709477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implications of opioid pharmacogenetics.
    Argoff CE
    Clin J Pain; 2010 Jan; 26 Suppl 10():S16-20. PubMed ID: 20026961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Genetic variation-- important for the clinical effect of opioids?].
    Klepstad P; Dale O; Borchgrevink PC; Kaasa S; Skorpen F
    Tidsskr Nor Laegeforen; 2005 Oct; 125(19):2655-8. PubMed ID: 16215614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action.
    Lötsch J; Skarke C; Wieting J; Oertel BG; Schmidt H; Brockmöller J; Geisslinger G
    Clin Pharmacol Ther; 2006 Jan; 79(1):72-89. PubMed ID: 16413243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics in pain management: the clinical need.
    Webster LR
    Clin Lab Med; 2008 Dec; 28(4):569-79. PubMed ID: 19059063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can heterogeneity of chronic sickle-cell disease pain be explained by genomics? A literature review.
    Adegbola MA
    Biol Res Nurs; 2009 Jul; 11(1):81-97. PubMed ID: 19487302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined catechol-O-methyltransferase and mu-opioid receptor gene polymorphisms affect morphine postoperative analgesia and central side effects.
    Kolesnikov Y; Gabovits B; Levin A; Voiko E; Veske A
    Anesth Analg; 2011 Feb; 112(2):448-53. PubMed ID: 21127283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects.
    Ross JR; Riley J; Taegetmeyer AB; Sato H; Gretton S; du Bois RM; Welsh KI
    Cancer; 2008 Mar; 112(6):1390-403. PubMed ID: 18257092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetic treatments for drug addiction: alcohol and opiates.
    Haile CN; Kosten TA; Kosten TR
    Am J Drug Alcohol Abuse; 2008; 34(4):355-81. PubMed ID: 18584566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A genetic association study of the functional A118G polymorphism of the human mu-opioid receptor gene in patients with acute and chronic pain.
    Janicki PK; Schuler G; Francis D; Bohr A; Gordin V; Jarzembowski T; Ruiz-Velasco V; Mets B
    Anesth Analg; 2006 Oct; 103(4):1011-7. PubMed ID: 17000822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the genetic determinants of pain and pain management.
    Miaskowski C
    Semin Oncol Nurs; 2009 May; 25(2 Suppl 1):S1-7. PubMed ID: 19447317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of CYP2D6 and OPRM1 pharmacogenetic testing for opioid therapy.
    Reynolds KK; Ramey-Hartung B; Jortani SA
    Clin Lab Med; 2008 Dec; 28(4):581-98. PubMed ID: 19059064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Postoperative pain management following orthognathic surgery in consideration of individual differences--is the antinociceptive effect of fentanyl related to the genotype involving nucleotide at OPRM1?].
    Fukuda K; Hayashida M; Ikeda K
    Masui; 2009 Sep; 58(9):1102-8. PubMed ID: 19764432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.